Inflazome to bring inflammasome inhibitors to clinic with €40M series B
Inflazome Ltd. (Dublin, Ireland) raised €40 million ($45.7 million) in a series B round on Nov. 19, giving it the funds to take several of its inflammasome inhibitors to the clinic next year, including a Parkinson's disease candidate.
New investors Forbion and Longitude Capital led the round; founding investors Novartis...
Read the full 228 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$35 USD
